HonCode

Go Back   HER2 Support Group Forums > her2group
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 12-20-2019, 03:55 PM   #1
Lani
Senior Member
 
Join Date: Mar 2006
Posts: 4,778
Lightbulb DS8201 accelerated approval by FDA

HEALTH NEWSDECEMBER 20, 2019 / 10:47 PM / UPDATED AN HOUR AGO
AstraZeneca, Daiichi's breast cancer drug gets accelerated approval from FDA
2 MIN READ
FREUTERS/Brendan McDermid
(Reuters) - The U.S. Food and Drug Administration said on Friday it had approved Daiichi Sankyo Co Ltd and AstraZeneca Plc’s drug to treat an advanced form of breast cancer, three months ahead of schedule.

AstraZeneca in March signed a licensing and collaboration deal that committed the British drugmaker to pay up to $6.9 billion to its Japanese partner Daiichi. (reut.rs/2sKMyIy)




The drug, Enhertu, comes with a boxed warning, the FDA’s strictest warning, flagging increased risk of lung disease and embryo-fetal toxicity.

The agency said further clinical trials may be required to verify and describe the benefits of Enhertu, which is still under development.




Enhertu, also known as DS-8201, targets HER2 protein, a major trigger of uncontrolled cell growth in about 20% cases of breast cancer, where Roche Holding AG has been a pioneer with its aging $7 billion-a-year best-seller Herceptin.

The FDA’s accelerated approval program allows a speedier market entry to medicines that fill an unmet medical need for a serious condition.

Reporting by Dania Nadeem in Bengaluru; Editing by Shinjini Ganguli
Our Standards:The Thomson Reuters Trust Principles.
Lani is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 03:21 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter